These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21941166)

  • 1. High-level, lasting antiviral immunity induced by a bimodal AIDS vaccine and boosted by live-virus exposure: prevention of viremia.
    Rasmussen RA; Siddappa NB; Lakhashe SK; Watkins J; Villinger F; Ibegbu C; Florese RH; Robert-Guroff M; Montefiori DC; Forthal DN; O'Connor D; Ruprecht RM;
    AIDS; 2012 Jan; 26(2):149-55. PubMed ID: 21941166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus.
    Kumar A; Mukherjee S; Shen J; Buch S; Li Z; Adany I; Liu Z; Zhuge W; Piatak M; Lifson J; McClure H; Narayan O
    Virology; 2002 Sep; 301(2):189-205. PubMed ID: 12359422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.
    Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ
    Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates.
    Bertley FM; Kozlowski PA; Wang SW; Chappelle J; Patel J; Sonuyi O; Mazzara G; Montefiori D; Carville A; Mansfield KG; Aldovini A
    J Immunol; 2004 Mar; 172(6):3745-57. PubMed ID: 15004179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection.
    Liu Q; Li Y; Luo Z; Yang G; Liu Y; Liu Y; Sun M; Dai J; Li Q; Qin C; Shao Y
    AIDS; 2015 Mar; 29(6):649-58. PubMed ID: 25849828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.
    Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic analysis reveals pre- and postchallenge differences in a rhesus macaque AIDS vaccine trial: insights into mechanisms of vaccine efficacy.
    Palermo RE; Patterson LJ; Aicher LD; Korth MJ; Robert-Guroff M; Katze MG
    J Virol; 2011 Jan; 85(2):1099-116. PubMed ID: 21068249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
    Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
    Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus.
    Sundling C; O'Dell S; Douagi I; Forsell MN; Mörner A; Loré K; Mascola JR; Wyatt RT; Karlsson Hedestam GB
    J Virol; 2010 Sep; 84(18):9086-95. PubMed ID: 20610729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Prime/Boost Vaccine Regimen Alters the Rectal Microbiome and Impacts Immune Responses and Viremia Control Post-Simian Immunodeficiency Virus Infection in Male and Female Rhesus Macaques.
    Musich T; Thovarai V; Venzon DJ; Mohanram V; Tuero I; Miller-Novak LK; Helmold Hait S; Rahman MA; Hunegnaw R; Huiting E; Yuan W; O'hUigin C; Hoang T; Sui Y; LaBranche C; Montefiori D; Bear J; Rosati M; Bissa M; Berzofsky JA; Pavlakis GN; Felber BK; Franchini G; Robert-Guroff M
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32967951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term control of simian immunodeficiency virus mac251 viremia to undetectable levels in half of infected female rhesus macaques nasally vaccinated with simian immunodeficiency virus DNA/recombinant modified vaccinia virus Ankara.
    Manrique M; Kozlowski PA; Cobo-Molinos A; Wang SW; Wilson RL; Montefiori DC; Mansfield KG; Carville A; Aldovini A
    J Immunol; 2011 Mar; 186(6):3581-93. PubMed ID: 21317390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239.
    Miller CJ; McChesney MB; Lü X; Dailey PJ; Chutkowski C; Lu D; Brosio P; Roberts B; Lu Y
    J Virol; 1997 Mar; 71(3):1911-21. PubMed ID: 9032322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppressing active replication of a live attenuated simian immunodeficiency virus vaccine does not abrogate protection from challenge.
    Gabriel B; Fiebig U; Hohn O; Plesker R; Coulibaly C; Cichutek K; Mühlebach MD; Bannert N; Kurth R; Norley S
    Virology; 2016 Feb; 489():1-11. PubMed ID: 26685794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Live-attenuated lentivirus immunization modulates innate immunity and inflammation while protecting rhesus macaques from vaginal simian immunodeficiency virus challenge.
    Genescà M; Ma ZM; Wang Y; Assaf B; Qureshi H; Fritts L; Huang Y; McChesney MB; Miller CJ
    J Virol; 2012 Sep; 86(17):9188-200. PubMed ID: 22696662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strong viremia control in vaccinated macaques does not prevent gradual Th17 cell loss from central memory.
    Demberg T; Ettinger AC; Aladi S; McKinnon K; Kuddo T; Venzon D; Patterson LJ; Phillips TM; Robert-Guroff M
    Vaccine; 2011 Aug; 29(35):6017-28. PubMed ID: 21708207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges.
    Hessell AJ; Shapiro MB; Powell R; Malherbe DC; McBurney SP; Pandey S; Cheever T; Sutton WF; Kahl C; Park B; Zolla-Pazner S; Haigwood NL
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection of macaques against a SHIV with a homologous HIV-1 Env and a pathogenic SHIV-89.6P with a heterologous Env by vaccination with multiple gene-deleted SHIVs.
    Ui M; Kuwata T; Igarashi T; Ibuki K; Miyazaki Y; Kozyrev IL; Enose Y; Shimada T; Uesaka H; Yamamoto H; Miura T; Hayami M
    Virology; 1999 Dec; 265(2):252-63. PubMed ID: 10600597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of viremia and maintenance of intestinal CD4(+) memory T cells in SHIV(162P3) infected macaques after pathogenic SIV(MAC251) challenge.
    Pahar B; Lackner AA; Piatak M; Lifson JD; Wang X; Das A; Ling B; Montefiori DC; Veazey RS
    Virology; 2009 May; 387(2):273-84. PubMed ID: 19298994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection.
    Mori K; Yasutomi Y; Sawada S; Villinger F; Sugama K; Rosenwith B; Heeney JL; Uberla K; Yamazaki S; Ansari AA; Rübsamen-Waigmann H
    J Virol; 2000 Jul; 74(13):5747-53. PubMed ID: 10846052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.